The partners in ASKLEPIOS aim to:

  1. Identify molecules that inhibit RABV replication
  2. Identify molecules that inhibit detrimental host responses to RABV infection:
  3. Show whether opening the blood-brain-barrier (BBB) improves treatment efficacy:
  4. Validate the potential of the molecules identified under 1 and 2 to be used as post-exposure prophylaxis (PEP) when classical PEP is ineffective.

In vivo testing of (combination of) therapeutic molecules

As a final part of the project, ASKLEPIOS will bring together the knowledge acquired in the different workpackages and use the mouse model to test the efficiency of the identified molecules to improve clinical course of rabies encephalitis. Molecules will …

Blood-brain barrier openers

The brain can be considered among the most important organs of an organism, where crucial information for vital functions is generated, processed and stored. Homeostatic balance in the brain is essential to ensure an organism’s normal function. Several mechanisms have …

Host-Response Inhibitors

Rabies encephalitis is not just an invariably deadly disease, patients with rabies experience an agonizing final stage of their life, due to the effect of the virus infection on neuronal function. Patients with rabies are fully aware of their neurological …

Virus Replication Inhibitors

Viruses are intracellular parasites that need the host-cell machinery for replication. Inhibiting virus replication using miRNA or siRNA has been described for several viruses. Although miRNAs have been shown to augment hepatitis C virus replication, a number of other host …